The effects of trazodone on human cognition: a systematic review

AbstractTrazodone is a widely used antidepressant that is also useful in the control of agitation and insomnia in Alzheimer's disease. This drug is now recognized as having a new mechanism of action, an effect on the unfolded protein response (UPR) pathway, restoring protein translation and slowing neurodegenerative progression in mice. This mechanism may have a role in dementia-modifying treatment.  To explore the effects of trazodone on human cognition and to search for clinical evidence of its putative benefits in human neurodegenerative diseases, a systematic review was conducted for studies that evaluated the effect of a minimum dose of 25 mg of trazodone daily, for at least 1 week, on cognition in adult humans. The search was run in MEDLINE, Web of Science, and CENTRAL from the Cochrane databases, yielding a total of 16 studies after selection. Overall, seven studies showed no effect of trazodone on cognition, five showed a beneficial effect by improving or reducing cognitive dec line, and four evidenced impaired cognitive function. Our analysis highlights the possibility of a dose-independent dual effect of trazodone on human cognition, with acute utilization associated with impaired cognitive function and long-term use with preventing cognitive deterioration. There was no clinical evidence that trazodone could be used as a specific treatment of neurodegenerative diseases. Future studies should explore the role of trazodone in the UPR pathway and the imp...
Source: European Journal of Clinical Pharmacology - Category: Drugs & Pharmacology Source Type: research

Related Links:

A 91-year-old man with probable Alzheimer dementia (Functional Assessment Staging Tool stage 6B, with no recent cognitive testing), major depressive disorder, insomnia, repeated falls, atrial fibrillation not on anticoagulation, hypertension, chronic kidney disease, urinary retention requiring self-catheterization, bilateral cataracts, osteoarthritis of the hips and lumbar spine, and constipation was seen in a memory-care unit after recent hospitalization for left hip fracture sustained in a ground-level fall.
Source: Mayo Clinic Proceedings - Category: Internal Medicine Authors: Tags: Residents ’ clinic Source Type: research
AbstractTrazodone is a widely used antidepressant that is also useful in the control of agitation and insomnia in Alzheimer's disease. This drug is now recognized as having a new mechanism of action, an effect on the unfolded protein response (UPR) pathway, restoring protein translation and slowing neurodegenerative progression in mice. This mechanism may have a role in dementia-modifying treatment.  To explore the effects of trazodone on human cognition and to search for clinical evidence of its putative benefits in human neurodegenerative diseases, a systematic review was conducted for studies that evaluated the eff...
Source: European Journal of Clinical Pharmacology - Category: Drugs & Pharmacology Source Type: research
Conclusion: There is strong evidence to suggest that CBT is associated with improvements in anxiety, depression, and quality of life in persons with mild cognitive impairment and dementia. CBT showed a reduction in insomnia and improvements in sleep quality. However, there is insufficient evidence to draw conclusions on the effects of CBT on insomnia. These results suggest that further investigation into insomnia outcomes is needed.
Source: Alzheimer Disease and Associated Disorders - Category: Geriatrics Tags: Review Articles Source Type: research
DISCUSSION: Short and long sleep duration and daytime napping in middle-aged individuals are associated with the development of dementia in later life. Sleep duration and quality are important for everyone regardless of their genetic risk by APOE genotype.PMID:34477303 | DOI:10.1002/alz.12439
Source: The Journal of Alzheimers Association - Category: Psychiatry Authors: Source Type: research
J Sleep Res. 2021 Aug 2:e13328. doi: 10.1111/jsr.13328. Online ahead of print.ABSTRACTThe orexin receptor antagonist suvorexant was previously reported to significantly improve total sleep time (TST), by 28 min per night versus placebo after 4 weeks, in a sleep laboratory polysomnography (PSG) study of patients with Alzheimer's disease and insomnia. The study included an exploratory evaluation of a consumer-grade wearable "watch" device for assessing sleep that we report on here. Participants who met diagnostic criteria for both probable Alzheimer's disease dementia and insomnia were randomized to suvorexant 10-2...
Source: Journal of Sleep Research - Category: Sleep Medicine Authors: Source Type: research
We examined insomnia symptoms and neuropsychological performance 3.4 years later in 511 dementia-free Framingham Heart Study participants (62.65 ± 8.7 years, 50.9% male). Additionally, we explored insomnia symptoms combined with self-reported short habitual sleep duration and effect modification by apolipoprotein E (APOE) ε4 allele status.RESULTS: More severe insomnia symptoms were associated with lower performance on global cognition, and immediate and delayed Logical Memory recall, especially when insomnia symptoms were combined with short sleep duration. The association between insomnia symptoms and poore...
Source: The Journal of Alzheimers Association - Category: Psychiatry Authors: Source Type: research
The most common type of dementia, Alzheimer's disease (AD), is characterized by progressive cognitive and functional decline. Nearly all patients with Alzheimer's disease (AD) develop neuropsychiatric symptoms, which include psychosis, agitation, depression, anxiety, and insomnia.1 Agitation, which can include aggressive behavior,2 occurs in one-third of community-dwelling patients with AD and is more common in nursing homes.1,3 Delusions and hallucinations occur in 15-30% and 5-15% of patients with AD, respectively.
Source: The American Journal of Geriatric Psychiatry - Category: Geriatrics Authors: Tags: Regular Research Article Source Type: research
This study aimed to investigate the risk and prognosis of Alzheimer's disease (AD) and vascular dementia (VaD) in patients with insomnia using the National Health Insurance Service database covering the entire population of the Republic of Korea from 2007 to 2014. In total, 2,796,871 patients aged 40 years or older with insomnia were enrolled, and 5,593,742 controls were matched using a Greedy digit match algorithm. Mortality and the rate of admission to a long-term care facility were estimated using multivariable Cox analysis. Of all patients with insomnia, 138,270 (4.94%) and 26,706 (0.96%) were newly diagnosed with AD a...
Source: Frontiers in Neurology - Category: Neurology Source Type: research
This study controlled for demographic characteristics including age, marital status, race, education, health conditions, and body weight. In the second study, researchers in Europe (including France, the United Kingdom, the Netherlands, and Finland) examined data from almost 8,000 participants from a different study and found that consistently sleeping six hours or less at age 50, 60, and 70 was associated with a 30% increase in dementia risk compared to a normal sleep duration of seven hours. The mean age of dementia diagnosis was 77 years. This study controlled for sociodemographic, behavioral, cardiometabolic, and menta...
Source: Harvard Health Blog - Category: Consumer Health News Authors: Tags: Alzheimer's Disease Healthy Aging Memory Neurological conditions Sleep Source Type: blogs
CONCLUSION: There is strong evidence to suggest that CBT is associated with improvements in anxiety, depression, and quality of life in persons with mild cognitive impairment and dementia. CBT showed a reduction in insomnia and improvements in sleep quality. However, there is insufficient evidence to draw conclusions on the effects of CBT on insomnia. These results suggest that further investigation into insomnia outcomes is needed.PMID:33929370 | DOI:10.1097/WAD.0000000000000454
Source: Alzheimer Disease and Associated Disorders - Category: Psychiatry Authors: Source Type: research
More News: Alzheimer's | Brain | Databases & Libraries | Dementia | Drugs & Pharmacology | Insomnia | Neurology | Neuroscience | Science | Study | Trazodone